Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$APPZ recent news/filings
## source: finance.yahoo.com
Wed, 13 Jan 2016 23:05:00 GMT ~ Monster Arts To Open Online Amazon And EBay Stores For Aviation M Product Offerings
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / January 13, 2016 / Monster Arts, Inc (OTCQB: APPZ) today announces that it has successfully tested the online store(s) services for EBay, and has decided to jump into ...
read full: http://finance.yahoo.com/news/monster-arts-open-online-amazon-230500992.html
*********************************************************
Wed, 16 Dec 2015 13:00:00 GMT ~ FAA Finally Decides to Call for Drone Registrations After 11 Months of Campaigning by Monster Arts
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / December 16, 2015 / Monster Arts, Inc (OTC:APPZ) today announces that after more than a year of encouraging federal, state, and local governments to adopt a drone registration ...
read full: http://finance.yahoo.com/news/faa-finally-decides-call-drone-130000140.html
*********************************************************
Fri, 11 Dec 2015 12:30:00 GMT ~ Monster Arts, Inc. Calling All Retired FAA Certified Instructors
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / December 11, 2015 / Monster Arts, Inc. (OTCQB:APPZ) announces that its begun seeking partnerships with retired and in-active FAA certified instructors to fulfill its ...
read full: http://finance.yahoo.com/news/monster-arts-inc-calling-retired-123000088.html
*********************************************************
Fri, 11 Dec 2015 11:04:39 GMT ~ MONSTER ARTS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Stat
read full: http://biz.yahoo.com/e/151211/appz8-k.html
*********************************************************
Tue, 08 Dec 2015 18:18:00 GMT ~ MONSTER ARTS INC. Financials
read full: http://finance.yahoo.com/q/is?s=appz
*********************************************************
$APPZ charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$APPZ company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/APPZ/company-info
Ticker: $APPZ
OTC Market Place: OTC Pink Current
CIK code: 0001423746
Company name: Monster Arts Inc.
Company website: http://www.monsterarts.net
Incorporated In: NV, USA
Business Description: Since 2010, Monster Arts, along with its corporate predecessors, affiliates, and venture partners, have been developing, and are continuing to develop, smart device GPS and intelligent-location driven tracking software, with a particular focus on the Drone/Unmanned Aerial Vehicle space as the next big area and opportunity for focusing its efforts. In addition, the Company continues to grow its paying subscriber and partner base, through FanPic.com andTravelAmericaVisitorGuide.com, among other projects.Less >>
$APPZ share structure
## source: otcmarkets.com
Market Value: $166,383 a/o Jan 14, 2016
Shares Outstanding: 1,663,832,173 a/o Nov 23, 2015
Float: Not Available
Authorized Shares: 5,000,000,000 a/o Apr 21, 2015
Par Value: Not Available
$APPZ extra dd links
Company name: Monster Arts Inc.
Company website: http://www.monsterarts.net
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=APPZ+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=APPZ+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=APPZ+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/news - http://finance.yahoo.com/q/h?s=APPZ+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/APPZ/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=APPZ+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/APPZ
DTCC (dtcc.com): http://search2.dtcc.com/?q=Monster+Arts+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Monster+Arts+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Monster+Arts+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.monsterarts.net
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.monsterarts.net#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.monsterarts.net
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/APPZ
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001423746&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=APPZ&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=APPZ
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=APPZ+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=APPZ+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=APPZ
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=APPZ
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=APPZ+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/APPZ/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=APPZ+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/APPZ.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=APPZ
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/APPZ
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/APPZ
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/APPZ:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=APPZ
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=APPZ
$APPZ recent news/filings
## source: finance.yahoo.com
Wed, 13 Jan 2016 23:05:00 GMT ~ Monster Arts To Open Online Amazon And EBay Stores For Aviation M Product Offerings
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / January 13, 2016 / Monster Arts, Inc (OTCQB: APPZ) today announces that it has successfully tested the online store(s) services for EBay, and has decided to jump into ...
read full: http://finance.yahoo.com/news/monster-arts-open-online-amazon-230500992.html
*********************************************************
Wed, 16 Dec 2015 13:00:00 GMT ~ FAA Finally Decides to Call for Drone Registrations After 11 Months of Campaigning by Monster Arts
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / December 16, 2015 / Monster Arts, Inc (OTC:APPZ) today announces that after more than a year of encouraging federal, state, and local governments to adopt a drone registration ...
read full: http://finance.yahoo.com/news/faa-finally-decides-call-drone-130000140.html
*********************************************************
Fri, 11 Dec 2015 12:30:00 GMT ~ Monster Arts, Inc. Calling All Retired FAA Certified Instructors
[Accesswire] - NORTH LAS VEGAS, NV / ACCESSWIRE / December 11, 2015 / Monster Arts, Inc. (OTCQB:APPZ) announces that its begun seeking partnerships with retired and in-active FAA certified instructors to fulfill its ...
read full: http://finance.yahoo.com/news/monster-arts-inc-calling-retired-123000088.html
*********************************************************
Fri, 11 Dec 2015 11:04:39 GMT ~ MONSTER ARTS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Stat
read full: http://biz.yahoo.com/e/151211/appz8-k.html
*********************************************************
Tue, 08 Dec 2015 18:18:00 GMT ~ MONSTER ARTS INC. Financials
read full: http://finance.yahoo.com/q/is?s=appz
*********************************************************
$APPZ charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$APPZ company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/APPZ/company-info
Ticker: $APPZ
OTC Market Place: OTC Pink Current
CIK code: 0001423746
Company name: Monster Arts Inc.
Company website: http://www.monsterarts.net
Incorporated In: NV, USA
Business Description: Since 2010, Monster Arts, along with its corporate predecessors, affiliates, and venture partners, have been developing, and are continuing to develop, smart device GPS and intelligent-location driven tracking software, with a particular focus on the Drone/Unmanned Aerial Vehicle space as the next big area and opportunity for focusing its efforts. In addition, the Company continues to grow its paying subscriber and partner base, through FanPic.com andTravelAmericaVisitorGuide.com, among other projects.Less >>
$APPZ share structure
## source: otcmarkets.com
Market Value: $166,383 a/o Jan 14, 2016
Shares Outstanding: 1,663,832,173 a/o Nov 23, 2015
Float: Not Available
Authorized Shares: 5,000,000,000 a/o Apr 21, 2015
Par Value: Not Available
$APPZ extra dd links
Company name: Monster Arts Inc.
Company website: http://www.monsterarts.net
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=APPZ+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=APPZ+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=APPZ+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/news - http://finance.yahoo.com/q/h?s=APPZ+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/APPZ/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=APPZ+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/APPZ
DTCC (dtcc.com): http://search2.dtcc.com/?q=Monster+Arts+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Monster+Arts+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Monster+Arts+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.monsterarts.net
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.monsterarts.net#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.monsterarts.net
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/APPZ
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001423746&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=APPZ&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=APPZ
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=APPZ+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=APPZ+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=APPZ
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=APPZ
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=APPZ+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/APPZ/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=APPZ+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/APPZ.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=APPZ
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/APPZ/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/APPZ/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/APPZ
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/APPZ
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/APPZ:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=APPZ
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=APPZ
$ABHI ~ AmbiCom Holdings, Inc. due diligence report
$ABHI recent news/filings
## source: finance.yahoo.com
Fri, 25 Dec 2015 18:04:20 GMT ~ AMBICOM HOLDINGS, INC Financials
read full: http://finance.yahoo.com/q/is?s=abhi
*********************************************************
Mon, 21 Dec 2015 22:31:39 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/151221/abhi10-q.html
*********************************************************
Tue, 17 Nov 2015 22:31:19 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 8-K, Change in Directors or Principal Officers
read full: http://biz.yahoo.com/e/151117/abhi8-k.html
*********************************************************
Fri, 13 Nov 2015 22:31:18 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 10-K, Annual Report
read full: http://biz.yahoo.com/e/151113/abhi10-k.html
*********************************************************
Thu, 08 Oct 2015 13:00:00 GMT ~ AmbiCom Retires Convertible Debt Vehicle
[Marketwired] - AmbiCom Holdings, Inc. , the leading provider of cloud based Active Optimization services for Personal Computers and servers has retired a convertible debt vehicle ahead of schedule.
read full: http://finance.yahoo.com/news/ambicom-retires-convertible-debt-vehicle-130000524.html
*********************************************************
$ABHI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ABHI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ABHI/company-info
Ticker: $ABHI
OTC Market Place: OTCQB
CIK code: 0001444310
Company name: AmbiCom Holdings, Inc.
Company website: http://www.ambicom.com
Incorporated In: NV, USA
Business Description: AmbiCom delivers its medical device OEM modules to many global medical device companies, including Cardinal Health/Carefusion, Siemens, Draeger and Roche.
$ABHI share structure
## source: otcmarkets.com
Market Value: $1,744 a/o Jan 25, 2016
Shares Outstanding: 17,436,282 a/o Dec 21, 2015
Float: 4,315,246 a/o Dec 04, 2014
Authorized Shares: 750,000,000 a/o Oct 31, 2015
Par Value: 0.001
$ABHI extra dd links
Company name: AmbiCom Holdings, Inc.
Company website: http://www.ambicom.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ABHI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ABHI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ABHI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/news - http://finance.yahoo.com/q/h?s=ABHI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ABHI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ABHI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ABHI
DTCC (dtcc.com): http://search2.dtcc.com/?q=AmbiCom+Holdings%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=AmbiCom+Holdings%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=AmbiCom+Holdings%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ambicom.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ambicom.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ambicom.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ABHI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001444310&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ABHI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ABHI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ABHI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ABHI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ABHI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ABHI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ABHI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ABHI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ABHI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ABHI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ABHI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ABHI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ABHI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ABHI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ABHI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ABHI
$ABHI ~ AmbiCom Holdings, Inc. due diligence report
$ABHI recent news/filings
## source: finance.yahoo.com
Fri, 25 Dec 2015 18:04:20 GMT ~ AMBICOM HOLDINGS, INC Financials
read full: http://finance.yahoo.com/q/is?s=abhi
*********************************************************
Mon, 21 Dec 2015 22:31:39 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/151221/abhi10-q.html
*********************************************************
Tue, 17 Nov 2015 22:31:19 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 8-K, Change in Directors or Principal Officers
read full: http://biz.yahoo.com/e/151117/abhi8-k.html
*********************************************************
Fri, 13 Nov 2015 22:31:18 GMT ~ AMBICOM HOLDINGS, INC Files SEC form 10-K, Annual Report
read full: http://biz.yahoo.com/e/151113/abhi10-k.html
*********************************************************
Thu, 08 Oct 2015 13:00:00 GMT ~ AmbiCom Retires Convertible Debt Vehicle
[Marketwired] - AmbiCom Holdings, Inc. , the leading provider of cloud based Active Optimization services for Personal Computers and servers has retired a convertible debt vehicle ahead of schedule.
read full: http://finance.yahoo.com/news/ambicom-retires-convertible-debt-vehicle-130000524.html
*********************************************************
$ABHI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ABHI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ABHI/company-info
Ticker: $ABHI
OTC Market Place: OTCQB
CIK code: 0001444310
Company name: AmbiCom Holdings, Inc.
Company website: http://www.ambicom.com
Incorporated In: NV, USA
Business Description: AmbiCom delivers its medical device OEM modules to many global medical device companies, including Cardinal Health/Carefusion, Siemens, Draeger and Roche.
$ABHI share structure
## source: otcmarkets.com
Market Value: $1,744 a/o Jan 25, 2016
Shares Outstanding: 17,436,282 a/o Dec 21, 2015
Float: 4,315,246 a/o Dec 04, 2014
Authorized Shares: 750,000,000 a/o Oct 31, 2015
Par Value: 0.001
$ABHI extra dd links
Company name: AmbiCom Holdings, Inc.
Company website: http://www.ambicom.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ABHI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ABHI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ABHI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/news - http://finance.yahoo.com/q/h?s=ABHI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ABHI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ABHI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ABHI
DTCC (dtcc.com): http://search2.dtcc.com/?q=AmbiCom+Holdings%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=AmbiCom+Holdings%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=AmbiCom+Holdings%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ambicom.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ambicom.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ambicom.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ABHI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001444310&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ABHI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ABHI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ABHI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ABHI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ABHI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ABHI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ABHI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ABHI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ABHI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ABHI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ABHI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ABHI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ABHI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ABHI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ABHI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ABHI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ABHI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ABHI
$SCIE ~ SpectraSCIENCE, Inc. due diligence report
$SCIE recent news/filings
## source: finance.yahoo.com
Tue, 02 Feb 2016 14:15:00 GMT ~ SpectraScience Announces Publication of Clinical Data
[Marketwired] - SpectraScience, Inc. , a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it had received notice that the results of an important clinical trial ...
read full: http://finance.yahoo.com/news/spectrascience-announces-publication-clinical-data-141500837.html
*********************************************************
Mon, 01 Feb 2016 13:50:00 GMT ~ Beyond the Chart, What Price Data Reveals - Complementary Research on SpectraScience, CV Sciences, Aytu BioScience and Imageware Systems
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/beyond-chart-price-data-reveals-135000038.html
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 15:26:32 GMT ~ SpectraScience to Display WavSTAT(R) Optical Biopsy System at Arab Health Conference
[Marketwired] - SpectraScience, Inc. , a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it will be exhibiting its WavSTAT Optical Biopsy System at the Arab Health ...
read full: http://finance.yahoo.com/news/spectrascience-display-wavstat-r-optical-152632894.html
*********************************************************
Tue, 05 Jan 2016 11:06:27 GMT ~ SPECTRASCIENCE INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibi
read full: http://biz.yahoo.com/e/160105/scie8-k.html
*********************************************************
$SCIE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SCIE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SCIE/company-info
Ticker: $SCIE
OTC Market Place: OTC Pink Current
CIK code: 0000727672
Company name: SpectraSCIENCE, Inc.
Company website: http://www.spectrascience.com
Incorporated In: MN, USA
Business Description: medical device manufacturer
$SCIE share structure
## source: otcmarkets.com
Market Value: $168,492 a/o Feb 09, 2016
Shares Outstanding: 210,615,011 a/o Nov 16, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$SCIE extra dd links
Company name: SpectraSCIENCE, Inc.
Company website: http://www.spectrascience.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCIE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCIE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCIE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/news - http://finance.yahoo.com/q/h?s=SCIE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCIE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCIE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCIE
DTCC (dtcc.com): http://search2.dtcc.com/?q=SpectraSCIENCE%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=SpectraSCIENCE%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=SpectraSCIENCE%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.spectrascience.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.spectrascience.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.spectrascience.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCIE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000727672&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCIE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCIE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCIE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCIE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCIE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCIE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCIE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCIE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCIE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCIE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCIE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCIE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCIE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCIE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCIE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCIE
$SCIE ~ SpectraSCIENCE, Inc. due diligence report
$SCIE recent news/filings
## source: finance.yahoo.com
Tue, 02 Feb 2016 14:15:00 GMT ~ SpectraScience Announces Publication of Clinical Data
[Marketwired] - SpectraScience, Inc. , a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it had received notice that the results of an important clinical trial ...
read full: http://finance.yahoo.com/news/spectrascience-announces-publication-clinical-data-141500837.html
*********************************************************
Mon, 01 Feb 2016 13:50:00 GMT ~ Beyond the Chart, What Price Data Reveals - Complementary Research on SpectraScience, CV Sciences, Aytu BioScience and Imageware Systems
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/beyond-chart-price-data-reveals-135000038.html
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 15:26:32 GMT ~ SpectraScience to Display WavSTAT(R) Optical Biopsy System at Arab Health Conference
[Marketwired] - SpectraScience, Inc. , a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it will be exhibiting its WavSTAT Optical Biopsy System at the Arab Health ...
read full: http://finance.yahoo.com/news/spectrascience-display-wavstat-r-optical-152632894.html
*********************************************************
Tue, 05 Jan 2016 11:06:27 GMT ~ SPECTRASCIENCE INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibi
read full: http://biz.yahoo.com/e/160105/scie8-k.html
*********************************************************
$SCIE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SCIE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SCIE/company-info
Ticker: $SCIE
OTC Market Place: OTC Pink Current
CIK code: 0000727672
Company name: SpectraSCIENCE, Inc.
Company website: http://www.spectrascience.com
Incorporated In: MN, USA
Business Description: medical device manufacturer
$SCIE share structure
## source: otcmarkets.com
Market Value: $168,492 a/o Feb 09, 2016
Shares Outstanding: 210,615,011 a/o Nov 16, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$SCIE extra dd links
Company name: SpectraSCIENCE, Inc.
Company website: http://www.spectrascience.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCIE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCIE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCIE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/news - http://finance.yahoo.com/q/h?s=SCIE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCIE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCIE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCIE
DTCC (dtcc.com): http://search2.dtcc.com/?q=SpectraSCIENCE%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=SpectraSCIENCE%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=SpectraSCIENCE%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.spectrascience.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.spectrascience.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.spectrascience.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCIE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000727672&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCIE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCIE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCIE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCIE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCIE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCIE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCIE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCIE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCIE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCIE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCIE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCIE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCIE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCIE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCIE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCIE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCIE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCIE
Yes...too much manipulated on the PPS. I will add more shares tomorrow at this level. MJNA will be a buy-out IMO
Go $MJNA
$PMCB PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
SILVER SPRING, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
Waggoner highlighted the 2016 milestones that PharmaCyte’s shareholders and investment community can look forward to this year:
PharmaCyte’s CEO will attend the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors.
The manufacturing facility in Bangkok, Thailand, where the live cells that convert the cancer prodrug ifosfamide into its cancer-killing form will be encapsulated, will receive a factory license from the Thai government enabling production of the encapsulated cells for PharmaCyte to use in its clinical trials.
The Austrianova manufacturing facility will become fully compliant with current Good Manufacturing Practices (cGMP) standards.
An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.
Appropriate arrangements will be made with cancer centers in the United States to begin PharmaCyte’s pancreatic cancer trial that will address the critical unmet medical need that exists when a patient’s non-metastatic, pancreatic cancer no longer benefits from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane®.
PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.
After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported to the public.
Additional preclinical studies to determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid will take place in 2016. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.
Numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017.
PharmaCyte will fill its open Board of Directors positions as appropriate.
PharmaCyte will conduct periodic shareholder calls, rather than communicating through shareholder updates, with the CEO responding to questions during the calls.
PharmaCyte will hold an annual shareholder meeting.
PharmaCyte’s Chief Operating Officer, Dr. Gerald W. Crabtree stated, “2016 promises to be both busy and productive for the Company and those associated with it. Of course the major highlight will be the start of our clinical trial in pancreatic cancer.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
SILVER SPRING, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
Waggoner highlighted the 2016 milestones that PharmaCyte’s shareholders and investment community can look forward to this year:
PharmaCyte’s CEO will attend the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors.
The manufacturing facility in Bangkok, Thailand, where the live cells that convert the cancer prodrug ifosfamide into its cancer-killing form will be encapsulated, will receive a factory license from the Thai government enabling production of the encapsulated cells for PharmaCyte to use in its clinical trials.
The Austrianova manufacturing facility will become fully compliant with current Good Manufacturing Practices (cGMP) standards.
An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.
Appropriate arrangements will be made with cancer centers in the United States to begin PharmaCyte’s pancreatic cancer trial that will address the critical unmet medical need that exists when a patient’s non-metastatic, pancreatic cancer no longer benefits from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane®.
PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.
After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported to the public.
Additional preclinical studies to determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid will take place in 2016. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.
Numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017.
PharmaCyte will fill its open Board of Directors positions as appropriate.
PharmaCyte will conduct periodic shareholder calls, rather than communicating through shareholder updates, with the CEO responding to questions during the calls.
PharmaCyte will hold an annual shareholder meeting.
PharmaCyte’s Chief Operating Officer, Dr. Gerald W. Crabtree stated, “2016 promises to be both busy and productive for the Company and those associated with it. Of course the major highlight will be the start of our clinical trial in pancreatic cancer.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the following developments since the Company’s last shareholder update:
PharmaCyte announced a complete redesign of its clinical trial in advanced pancreatic cancer. After consulting with world-renowned experts in the filed of pancreatic cancer; including, Dr. Mathias Löhr, Dr. Manuel Hidalgo, and experts at Translational Drug Development (TD2), PharmaCyte’s Phase 2b clinical trial was completely redesigned in an attempt to satisfy a critical unmet medical need that exists for patients with inoperable, but not metastatic, pancreatic cancer whose tumors no longer respond after 4 to 6 months of treatment with the current “gold standard” for the disease, the combination of Abraxane® plus gemcitabine. In most cases, therapy consisting of another chemotherapy agent plus radiation is given to such patients. However, the beneficial effects of these treatments are marginal at best.
The clinical trial will now be conducted in the United States by TD2 with study sites in both Europe and Australia.
Eligible patients will be randomly placed into two groups. Group 1 will receive PharmaCyte’s pancreatic cancer treatment of Cell-in-a-Box® plus low doses of ifosfamide. Group 2 will receive treatment with the combination of capecitabine + radiation.
The primary endpoints for the trial will be: (i) progression-free survival (PSF); and (ii) the side effects that occur in the patients. PSF is the time that elapses from the first day of treatment until the disease gets worse. The trial design also includes several secondary endpoints; the most important of which are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patients’ overall quality of life during the treatment.
PharmaCyte will now include in this trial the evaluation of its pancreatic cancer treatment on the treatment of pain, a severe consequence of pancreatic cancer. A separate clinical trial on pancreatic cancer pain is no longer necessary.
Regarding PharmaCyte’s work on ascites fluid production and accumulation, a series of additional preclinical studies has been initiated and are being continued by TD2. The initial studies using an ovarian tumor model in mice indicated that PharmaCyte’s pancreatic cancer treatment might have value in treating the malignant ascites fluid condition. These preclinical studies are now being continued with other abdominal tumor models, beginning with colon cancer, in an effort to better define the conditions under which PharmaCyte’s pancreatic cancer treatment can modulate the production or accumulation of malignant ascites fluid.
In late 2015, PharmaCyte obtained the Orphan Drug designation (ODD) for its pancreatic cancer treatment from the European Medicines Agency (EMA). With this designation, PharmaCyte now has ODD in Europe and the United States, which was obtained in late 2014 when the FDA granted the ODD to PharmaCyte. Obtaining the ODD allows for 10 years of marketing exclusivity in the European Union and 7 years of marketing exclusivity in the United States upon approval by the EMA and the FDA of PharmaCyte’s pancreatic cancer treatment.
PharmaCyte appointed Dr. Manuel Hidalgo as a member of its Scientific Advisory Board and as a consultant. For several years, Dr. Hidalgo worked closely with pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2. Recently, Dr. Hidalgo was appointed Head of Hematology and Oncology at the Beth Israel Deaconess Hospital in Boston, an institution that is affiliated with the renowned Dana-Farber Cancer Institute in Boston.
PharmaCyte contracted with Imaging Endpoints, one of America’s leading Contract Research Organizations for radiologic imaging, to perform the radiologic imaging that will be the cornerstone of many of the measurements conducted during the pancreatic cancer clinical trial.
Prior to the initiation of a clinical trial, an Investigational New Drug Application (IND) must be filed and reviewed by the FDA. A major part of the IND is a section termed “Chemistry, Manufacturing and Controls” or “CMC.” Within the CMC section, a pivotal portion describes the characteristics of the drug or treatment production facility and supplies supporting documentation to ensure that the facility meets cGMP standards. PharmaCyte retained CMC experts Chamow and Associates (Chamow) to assist in evaluating the facility in Bangkok, Thailand, that will produce and supply the Cell-in-a-Box® technology for PharmaCyte’s clinical trial, and in preparing the relevant portions of the CMC section of the IND for submission to the FDA and other regulatory agencies. PharmaCyte and TD2 are awaiting receipt of Chamow’s audit report to finalize the timeline for commencement of the clinical trial.
In November 2015, the second annual meeting of the international Diabetes Consortium was held in Vienna, Austria. Members of the Consortium presented results of studies done to date and finalized research plans for future studies. A video that discusses PharmaCyte’s diabetes program was filmed at the meeting and can be viewed at www.PharmaCyte.com/diabetes.
A guest at the meeting of the Diabetes Consortium was Prof. Dr. Hans-Peter Hammes, one of Europe’s leading authorities on diabetes and its complications. Dr. Hammes currently serves as Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim at the University of Heidelberg in Germany. Dr. Hammes received the prestigious Camillo Golgi Prize awarded at the 2015 meeting of the European Association for the Study of Diabetes. After attending the Diabetes Consortium meeting and becoming acquainted with the Consortium members, Dr. Hammes agreed to join PharmaCyte’s Scientific Advisory Board and become a member of the Consortium. Dr. Hammes also agreed to serve as a consultant to PharmaCyte.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the following developments since the Company’s last shareholder update:
PharmaCyte announced a complete redesign of its clinical trial in advanced pancreatic cancer. After consulting with world-renowned experts in the filed of pancreatic cancer; including, Dr. Mathias Löhr, Dr. Manuel Hidalgo, and experts at Translational Drug Development (TD2), PharmaCyte’s Phase 2b clinical trial was completely redesigned in an attempt to satisfy a critical unmet medical need that exists for patients with inoperable, but not metastatic, pancreatic cancer whose tumors no longer respond after 4 to 6 months of treatment with the current “gold standard” for the disease, the combination of Abraxane® plus gemcitabine. In most cases, therapy consisting of another chemotherapy agent plus radiation is given to such patients. However, the beneficial effects of these treatments are marginal at best.
The clinical trial will now be conducted in the United States by TD2 with study sites in both Europe and Australia.
Eligible patients will be randomly placed into two groups. Group 1 will receive PharmaCyte’s pancreatic cancer treatment of Cell-in-a-Box® plus low doses of ifosfamide. Group 2 will receive treatment with the combination of capecitabine + radiation.
The primary endpoints for the trial will be: (i) progression-free survival (PSF); and (ii) the side effects that occur in the patients. PSF is the time that elapses from the first day of treatment until the disease gets worse. The trial design also includes several secondary endpoints; the most important of which are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patients’ overall quality of life during the treatment.
PharmaCyte will now include in this trial the evaluation of its pancreatic cancer treatment on the treatment of pain, a severe consequence of pancreatic cancer. A separate clinical trial on pancreatic cancer pain is no longer necessary.
Regarding PharmaCyte’s work on ascites fluid production and accumulation, a series of additional preclinical studies has been initiated and are being continued by TD2. The initial studies using an ovarian tumor model in mice indicated that PharmaCyte’s pancreatic cancer treatment might have value in treating the malignant ascites fluid condition. These preclinical studies are now being continued with other abdominal tumor models, beginning with colon cancer, in an effort to better define the conditions under which PharmaCyte’s pancreatic cancer treatment can modulate the production or accumulation of malignant ascites fluid.
In late 2015, PharmaCyte obtained the Orphan Drug designation (ODD) for its pancreatic cancer treatment from the European Medicines Agency (EMA). With this designation, PharmaCyte now has ODD in Europe and the United States, which was obtained in late 2014 when the FDA granted the ODD to PharmaCyte. Obtaining the ODD allows for 10 years of marketing exclusivity in the European Union and 7 years of marketing exclusivity in the United States upon approval by the EMA and the FDA of PharmaCyte’s pancreatic cancer treatment.
PharmaCyte appointed Dr. Manuel Hidalgo as a member of its Scientific Advisory Board and as a consultant. For several years, Dr. Hidalgo worked closely with pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2. Recently, Dr. Hidalgo was appointed Head of Hematology and Oncology at the Beth Israel Deaconess Hospital in Boston, an institution that is affiliated with the renowned Dana-Farber Cancer Institute in Boston.
PharmaCyte contracted with Imaging Endpoints, one of America’s leading Contract Research Organizations for radiologic imaging, to perform the radiologic imaging that will be the cornerstone of many of the measurements conducted during the pancreatic cancer clinical trial.
Prior to the initiation of a clinical trial, an Investigational New Drug Application (IND) must be filed and reviewed by the FDA. A major part of the IND is a section termed “Chemistry, Manufacturing and Controls” or “CMC.” Within the CMC section, a pivotal portion describes the characteristics of the drug or treatment production facility and supplies supporting documentation to ensure that the facility meets cGMP standards. PharmaCyte retained CMC experts Chamow and Associates (Chamow) to assist in evaluating the facility in Bangkok, Thailand, that will produce and supply the Cell-in-a-Box® technology for PharmaCyte’s clinical trial, and in preparing the relevant portions of the CMC section of the IND for submission to the FDA and other regulatory agencies. PharmaCyte and TD2 are awaiting receipt of Chamow’s audit report to finalize the timeline for commencement of the clinical trial.
In November 2015, the second annual meeting of the international Diabetes Consortium was held in Vienna, Austria. Members of the Consortium presented results of studies done to date and finalized research plans for future studies. A video that discusses PharmaCyte’s diabetes program was filmed at the meeting and can be viewed at www.PharmaCyte.com/diabetes.
A guest at the meeting of the Diabetes Consortium was Prof. Dr. Hans-Peter Hammes, one of Europe’s leading authorities on diabetes and its complications. Dr. Hammes currently serves as Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim at the University of Heidelberg in Germany. Dr. Hammes received the prestigious Camillo Golgi Prize awarded at the 2015 meeting of the European Association for the Study of Diabetes. After attending the Diabetes Consortium meeting and becoming acquainted with the Consortium members, Dr. Hammes agreed to join PharmaCyte’s Scientific Advisory Board and become a member of the Consortium. Dr. Hammes also agreed to serve as a consultant to PharmaCyte.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB If You Like Islet Sciences, You'll Love Pharmacyte Biotech
Islet Sciences Inc. (OTCMKTS:ISLT) shares were all the rage on Monday, but Pharmacyte Biotech Inc. (OTCMKTS:PMCB) remains one of the market's most compelling penny stocks in the diabetes treatment space.
Congratulations to anyone who happened to own Islet Sciences Inc. (OTCMKTS:ISLT) before Friday's close. ISLT shares shot out of the gate on Monday morning, end the day with a 250% gain... proving penny stocks can and do pay off when the timing and story is right. If you're serious about tapping into the next era of diabetes treatments, though, then you may want to lock in what you can while you can with Islet Sciences and then take a closer look at Pharmacyte Biotech Inc. (OTCMKTS:PMCB). It's developing a novel diabetes therapy of its own, and could change the way we think about treating the dreaded disease.
Don't look for any particular reason something news-related lit a fire under ISLT on Monday - you won't find it. Sometimes penny stocks just strike the right cord with the right group of people and develop a life of their own.
That's not to take away from the work Islet Sciences has done. It's work in the area of creating immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction has been eye-opening, and shows promise. Specifically, Islet Sciences Inc. has found that microencapsulated -- protected -- porcine islets injected into the abdominal cavity can effectively serve as a transplanted pancreas for diabetic patients. What's not clear is the longevity of the encapsulated cells. In trials this far, 85% of transplantees remained insulin-independent at the one-year mark, but a 15% attrition rate in just the first year doesn't necessarily bode well as a long-term fix given the surgery involved.
It's akin to an approach Pharmacyte Biotech is taking to treat diabetes as well, but perhaps with a little more promise.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed in the leg near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
The key is the polymer used to encapsulate living cells.
The manufacturing process begins with the mix of live cells (insulin-producing Melligen cells, in this case) and a polymer which are sent through a droplet-forming machine and into a small vat of another proprietary polymer. When the two polymers join, a membrane is formed, with the living cells inside of it. This shell keeps the cells inside, yet lets insulin out, while allowing nutrients in, and waste out. Most important though, the shell keeps the body's own immune system from killing these cells.... something most previous encapsulation approaches didn't do. A handful of these pinhead-sized capsules containing Melligen cells can replace the insulin-producing function of the pancreas from some other site in the body.
Cell-in-a-Box as a therapy for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials
It's a major leap forward for diabetics - an encapsulation biotechnology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials.
And yes, though still in preclinical testing, the premise has been proven safe.
The work will be worth the effort. The diabetes treatment market is worth an estimated $7 billion per year, and Cell-in-a-Box is effectively a cure for it that abates the need for needles. In the meantime, investors are apt to reward the stock as the company achieves critical milestones en route to the endzone.
None of this is to take away from what Islet Sciences has done, or any other penny stocks of companies working on diabetes therapies. All that other work, however, underscores just how game-changing PMCB could be in the world of diabetes.
$PMCB PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
SILVER SPRING, Md., Jan. 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We have a lot of work ahead of us this year at PharmaCyte. With the recently announced private placement of just over $1 million, we have not only increased our cash on hand to over $3.0 million but have increased our leverage in the capital markets. What is mission critical for PharmaCyte is getting into a pancreatic cancer clinical trial and producing the data that is necessary for us to approach the FDA. We have every expectation that will occur this year.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
SILVER SPRING, Md., Jan. 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We have a lot of work ahead of us this year at PharmaCyte. With the recently announced private placement of just over $1 million, we have not only increased our cash on hand to over $3.0 million but have increased our leverage in the capital markets. What is mission critical for PharmaCyte is getting into a pancreatic cancer clinical trial and producing the data that is necessary for us to approach the FDA. We have every expectation that will occur this year.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB Press Release
AUSTRIANOVA EXPANDS ITS BUSINESS AREA
JANUARY 26, 2016 EPR BIOTECH NEWS
LEAVE A COMMENT
SINGAPORE, January 26, 2016 — /EPR BIOTECH NEWS/ — Austrianova announced today that, having completed the set up of austrianova logoits new GMP facility, it is now offering clients a GMP cell banking (Master Cell Bank and Working Cell Bank) as well as a “Fill and Finish” service for cell therapy products, in addition to its encapsulation services and technology. Austrianova is able to offer the production of Master Cell and Working Cell Banks (MCB and WCB) at the size scale required for early (phase 1 and 2) stage clinical trials at highly competitive prices using its state of the art isolator based production facility, assuring that the highest quality standards are adhered to. The company can also fill bulk cell product into syringes or vials in its GMP facility. This new cell banking and filling service is called GMP4Cells. MCB’s and WCB’s are required for all cell therapy products such as stem cell therapies as well as biologics produced from cells such as vaccines, antibodies, recombinant proteins etc. Similarly, many companies, including those developing stem cell lines and products, are seeking high quality economic fill and finish for relative small lots.
“We see this as a natural add-on to our already established Cell-in-a-Box® cell encapsulation technology for which we have recently set up a GMP manufacturing facility in Thailand. This kind of MCB and WCB production as well as “Fill and Finish” services for cells are, however, stand alone services. Although these services are generally available to all customers, they should allow start up companies and academic based cell products, vaccines etc to enter clinical trials in a quality assured manner but at lower cost that other, more conventional, cell banking companies offer” stated Walter H. Gunzburg, Chairman and CTO of Austrianova.
“In addition to our state of the art facility, Austrianova offers services that comply with major international regulatory agencies using a customized German/Swiss based quality assurance system. Our team has many years experience with regulatory agencies around the world and has taken cell therapies into clinical trials” said Brian Salmons, CEO.
More information about the GMP4Cells cell banking but also the Cell-in-a-Box® and the related Bac-in-a-Box® encapsulation services can be found on our newly revamped website www.austrianova.com.
About Austrianova:
Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.
Austrianova Singapore Pte Ltd,
#05-19 Synapse,
3 Biopolis Drive,
Singapore 138623
Tel +65 6779 3867
Fax: +65 6268 4671
Austrianova Thailand Co., Ltd,
141 INC2 Building D, Room 401-404
Thailand Science Park,
Paholyothin Road, Klong 1,
Klong Luang, Pathumthani 12120,
Thailand
www.austrianova.com
http://www.eprbiotechnews.com/2016/01/26/austrianova-expands-its-business-area/
$PMCB Press Release
AUSTRIANOVA EXPANDS ITS BUSINESS AREA
JANUARY 26, 2016 EPR BIOTECH NEWS
LEAVE A COMMENT
SINGAPORE, January 26, 2016 — /EPR BIOTECH NEWS/ — Austrianova announced today that, having completed the set up of austrianova logoits new GMP facility, it is now offering clients a GMP cell banking (Master Cell Bank and Working Cell Bank) as well as a “Fill and Finish” service for cell therapy products, in addition to its encapsulation services and technology. Austrianova is able to offer the production of Master Cell and Working Cell Banks (MCB and WCB) at the size scale required for early (phase 1 and 2) stage clinical trials at highly competitive prices using its state of the art isolator based production facility, assuring that the highest quality standards are adhered to. The company can also fill bulk cell product into syringes or vials in its GMP facility. This new cell banking and filling service is called GMP4Cells. MCB’s and WCB’s are required for all cell therapy products such as stem cell therapies as well as biologics produced from cells such as vaccines, antibodies, recombinant proteins etc. Similarly, many companies, including those developing stem cell lines and products, are seeking high quality economic fill and finish for relative small lots.
“We see this as a natural add-on to our already established Cell-in-a-Box® cell encapsulation technology for which we have recently set up a GMP manufacturing facility in Thailand. This kind of MCB and WCB production as well as “Fill and Finish” services for cells are, however, stand alone services. Although these services are generally available to all customers, they should allow start up companies and academic based cell products, vaccines etc to enter clinical trials in a quality assured manner but at lower cost that other, more conventional, cell banking companies offer” stated Walter H. Gunzburg, Chairman and CTO of Austrianova.
“In addition to our state of the art facility, Austrianova offers services that comply with major international regulatory agencies using a customized German/Swiss based quality assurance system. Our team has many years experience with regulatory agencies around the world and has taken cell therapies into clinical trials” said Brian Salmons, CEO.
More information about the GMP4Cells cell banking but also the Cell-in-a-Box® and the related Bac-in-a-Box® encapsulation services can be found on our newly revamped website www.austrianova.com.
About Austrianova:
Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.
Austrianova Singapore Pte Ltd,
#05-19 Synapse,
3 Biopolis Drive,
Singapore 138623
Tel +65 6779 3867
Fax: +65 6268 4671
Austrianova Thailand Co., Ltd,
141 INC2 Building D, Room 401-404
Thailand Science Park,
Paholyothin Road, Klong 1,
Klong Luang, Pathumthani 12120,
Thailand
www.austrianova.com
http://www.eprbiotechnews.com/2016/01/26/austrianova-expands-its-business-area/
$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer
Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.
For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.
The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.
Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.
Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.
While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).
That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.
The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.
$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer
Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.
For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.
The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.
Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.
Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.
While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).
That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.
The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
$PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 08 Feb 2016 14:00:00 GMT ~ Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
[Marketwired] - Johnson & Johnson , like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, ...
read full: http://finance.yahoo.com/news/johnson-johnson-big-pharma-could-140000750.html
*********************************************************
Tue, 02 Feb 2016 12:30:00 GMT ~ Where are the Traders Headed - Analyst Notes on CD International Enterprises, Valley High Mining, Pharmacyte Biotech and Bombardier
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International ...
read full: http://finance.yahoo.com/news/where-traders-headed-analyst-notes-123000207.html
*********************************************************
Mon, 01 Feb 2016 14:05:00 GMT ~ Trading Ahead of Upcoming Developments -- New Research on Trans-Pacific Aerospace Company, Pharmacyte Biotech, First Mining Finance, and Accretive Health
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific ...
read full: http://finance.yahoo.com/news/trading-ahead-upcoming-developments-research-140500683.html
*********************************************************
Thu, 28 Jan 2016 12:43:00 GMT ~ Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / January 28, 2016 / There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are ...
read full: http://finance.yahoo.com/news/presidential-elections-put-cannabis-cannabis-124300853.html
*********************************************************
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $51,807,051 a/o Feb 08, 2016
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB